Európai Unió - portugál - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, tipo 2 - drogas usadas em diabetes - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 e 5. 1 para dados disponíveis em diferentes combinações).

Európai Unió - portugál - EMA (European Medicines Agency)

accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - agentes antineoplásicos - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

Európai Unió - portugál - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriflunomide - esclerose múltipla remitente-recorrente envio - imunosupressão, seletiva imunosupressão - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Európai Unió - portugál - EMA (European Medicines Agency)

accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - immunostimulants, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.

Európai Unió - portugál - EMA (European Medicines Agency)

accord healthcare s.l.u. - fumarato de dimetilo - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunossupressores - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Európai Unió - portugál - EMA (European Medicines Agency)

accord healthcare s.l.u. - degarelix acetate - neoplasias prostáticas - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Portugália - portugál - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

accord healthcare, s.l.u. - linezolida - solução para perfusão - 600 mg/300 ml - linezolida 2 mg/ml - linezolid - genérico - duração do tratamento: curta ou média duração

Portugália - portugál - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

accord healthcare, s.l.u. - fenitoína - solução injetável - 250 mg/5 ml - fenitoína sódica 50 mg/ml - phenytoin - genérico - duração do tratamento: longa duração

Portugália - portugál - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

accord healthcare, s.l.u. - clofarabina - concentrado para solução para perfusão - 1 mg/ml - clofarabina 1 mg/ml - clofarabine - genérico - duração do tratamento: longa duração

Portugália - portugál - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

accord healthcare, s.l.u. - remifentanilo - pó para concentrado para solução injetável ou para perfusão - 1 mg - remifentanilo, cloridrato 1.1 mg - remifentanil - genérico - duração do tratamento: longa duração